Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

NCT01687699 is registered in ClinicalTrials.gov with Dialysis Outcomes Heart Failure Aldactone Study Group as lead sponsor.

NCT NCT01687699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01687699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Lead sponsor
Dialysis Outcomes Heart Failure Aldactone Study Group
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2008
Completion date
Not reported
Enrollment
157 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal failure